Thursday, October 27, 2022 1:54:01 AM
About ANITAC™ Degraders Androgen receptor signaling is the main driver of prostate cancer progression and remains a crucial target for therapeutic intervention in late stages of the disease. While current antiandrogen therapies that directly or indirectly target the AR ligand-binding domain (LBD) are initially effective, resistance ultimately develops and new methods of inhibiting the AR pathway are needed.
ESSA's novel approach of targeting the N-terminal domain of the AR represents a new method of blocking AR signaling. Leveraging ESSA's scientific foundation in successfully targeting the NTD of the AR with a new class of small molecules called anitens, ESSA is developing the first generation of ANITen bAsed Chimera degraders targeting the AR NTD. In preclinical models, the orally bioavailable ANITAC degraders can eliminate forms of AR protein found in castration-resistant prostate cancer that can potentially drive disease progression including LBD mutants and LBD truncated splice variants.
Recent EPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:01:43 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 11:00:44 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 • PR Newswire (US) • 08/05/2024 11:00:00 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024 • PR Newswire (Canada) • 08/05/2024 11:00:00 AM
- ESSA Pharma to Present at the JonesHealthcare Seaside Summit • PR Newswire (Canada) • 07/08/2024 08:05:00 PM
- ESSA Pharma to Present at the JonesHealthcare Seaside Summit • PR Newswire (US) • 07/08/2024 08:05:00 PM
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:00:00 PM
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (Canada) • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:01:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 11:00:36 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (Canada) • 05/14/2024 11:00:00 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (US) • 05/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:17:29 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (Canada) • 04/09/2024 12:00:00 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (US) • 04/09/2024 12:00:00 PM
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS • PR Newswire (US) • 03/08/2024 01:13:00 AM
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS • PR Newswire (Canada) • 03/08/2024 01:13:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:18:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:50:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 12:01:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:01:41 PM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 • PR Newswire (Canada) • 02/13/2024 12:00:00 PM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 04:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:27:19 PM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM